Lupus News Today Home | Lupus News Today
WEB4 days ago · Parvovirus, mpox, and COVID-19: 3 reasons to heighten precautions. Summer news reports show that COVID-19 is surging again. The World Health Organization has declared the mpox outbreak a global health emergency. And human parvovirus B19, which can cause fifth disease, is spreading across the …
Lupkinis plus MMF most effective as treatment for lupus nephritis
WEBby Andrea Lobo, PhD January 8, 2024. A combination of Lupkinis (viclosporin) with mycophenolate mofetil (MMF) was the most effective at managing lupus nephritis, according to a systematic review of clinical trial data. The treatment was also associated with the highest risk of infections and serious infections, indicating a lower safety profile ...
Lupkynis approved in Japan to treat lupus nephritis
WEB2 days ago · Lupkynis (voclosporin) is now approved in Japan to treat lupus nephritis, a complication of lupus marked by kidney damage and inflammation. The Japanese Ministry of Health, Labour, and Welfare approved the treatment’s use in combination with the immunosuppressant mycophenolate mofetil. Otsuka Pharmaceutical filed a new drug application with ...
Lupkynis protects kidneys in lupus nephritis for up to 3 years
WEBJul 24, 2023 · The therapy is an oral medication approved in US, UK, and EU. by Margarida Maia July 24, 2023. Lupkynis (voclosporin) continues to be safe and to protect kidney function when taken for up to three years by patients with lupus nephritis, a kidney complication of lupus. That’s according to the full results from AURORA 2 …
1st patient enrolled in global Phase 2 trial of daxdilimab for...
WEBMay 18, 2023 · A Phase 2 trial evaluating the safety and efficacy of daxdilimab, a potentially first-in-class treatment for people with active, proliferative lupus nephritis (LN) — a lupus complication marked by kidney damage — has enrolled its first patient.
LRA awards scientists $600K for work into new treatments for lupus
WEBby Mary Chapman March 14, 2024. The Lupus Research Alliance (LRA) has announced the latest recipients of its Lupus Mechanisms and Targets Award (LMTA), who will investigate molecular pathways or targets that could lead to new or better treatments for lupus. Each of the seven awarded scientists will receive up to $600,000 in funding over three ...
Lupkynis helps protect kidneys with lupus nephritis and high...
WEBJun 12, 2023 · Lupkynis is approved in the U.S., European Union, and the U.K. as an oral treatment for adults with active lupus nephritis when combined with background immunosuppressant therapy, including mycophenolate mofetil and corticosteroids. It works by blocking the activity of a protein called calcineurin — a mechanism thought to reduce inflammation and stabilize kidney cells.
Lupuzor Shows Strong Safety Results as Lupus Treatment in Phase …
WEBby Alice Melão September 29, 2017. New data from an ongoing Phase 3 clinical trial continues to demonstrate that ImmuPharma ‘s Lupuzor is safe for the treatment of systemic lupus erythematosus (SLE) patients. To date, all trial participants have reached the six-month stage, and one out of four have completed the full 12-month study.
Lupus overview - Lupus News Today
WEBFeb 9, 2023 · Lupus is a chronic disorder wherein the immune system attacks the body’s own healthy tissue. Lupus can affect virtually every part of the body, including the skin, kidneys, joints, brain, heart, and lungs, resulting in a range of symptoms. Systemic lupus erythematosus (SLE) — often referred to simply as lupus — is the most common and ...
News Archives - Lupus News Today
WEBJoint pain very common in lupus, affects patients’ life quality: Study. The vast majority of people with systemic lupus erythematosus (SLE) experience musculoskeletal symptoms, marked by pain, ache, discomfort, and numbness, often in the joints, primarily the hands, wrists, and knees. That’s according to a study from researchers in Egypt ...